The search for novel therapeutic strategies in HNSCC has increasingly focused on signaling pathways that drive resistance to established treatments, particularly the insulin receptor substrates (IRS1/2) and the signal transducer and activator of transcription 3 (STAT3) axis [80]. Here, STAT3 is linked to head and neck squamous cell carcinoma.